Correction: Targeting BATF2-RGS2 axis reduces T-cell exhaustion and restores anti-tumor immunity [0.03%]
纠正：靶向BATF2-RGS2轴可减轻T细胞衰竭并恢复抗肿瘤免疫功能
Xuyu Gu,Chanchan Gao,Xiangyu Su et al.
Xuyu Gu et al.
Published Erratum
Molecular cancer. 2025 Jun 23;24(1):182. DOI:10.1186/s12943-025-02387-7 2025
Extracellular vesicles: the "Trojan Horse" within breast cancer host microenvironments [0.03%]
乳腺癌宿主微环境中的外泌体：“特洛伊木马”
Yue Kang,Ling&#x;ao Meng,Shi Bai et al.
Yue Kang et al.
Breast cancer represents a significant global health concern among women. The intricate processes and pathways underlying metastasis contribute to the challenging prognoses experienced by some patients. Extracellular vesicles (EVs) are memb...
Aurora kinases signaling in cancer: from molecular perception to targeted therapies [0.03%]
癌症中的 Aurora 激酶信号通路：从分子机制到靶向治疗
Prerna Vats,Chainsee Saini,Bhavika Baweja et al.
Prerna Vats et al.
Aurora kinases, AURKA, AURKB, and AURKC, are serine/threonine kinases that play a vital role in regulating cell division and mitosis, particularly in the separation of chromosomes. These kinases are often overexpressed in human tumor cell l...
Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment [0.03%]
用于透明细胞肾细胞癌治疗的生物靶向双重适应性和先天性纳米免疫疗法
Kin Man Au,Siqing Li,Tian Zhang et al.
Kin Man Au et al.
Background: Immunotherapy treatments have significantly improved metastatic renal cell carcinoma (RCC) treatment outcomes. Despite recent advancements, the rates of durable response to immunotherapy remain low, and the to...
Single-cell multi-omics reveals that FABP1 + renal cell carcinoma drive tumor angiogenesis through the PLG-PLAT axis under fatty acid reprogramming [0.03%]
单细胞多组学揭示FABP1+肾癌细胞通过脂肪酸重编程下PLG-PLAT轴促进肿瘤血管生成
Yiqiu Wang,Yingchun Liang,Min Li et al.
Yiqiu Wang et al.
Renal cell carcinoma is characterized by a poor prognosis. Recently, renal cell carcinoma has been recognized as a metabolic disease associated with fatty acid metabolic reprogramming, although in-depth studies on this topic are still lacki...
Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment [0.03%]
揭秘cGAS-STING通路：肿瘤免疫微环境中精准调控机制
Qingyang Wang,Yang Yu,Jing Zhuang et al.
Qingyang Wang et al.
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway serves as an immune sentinel for cytosolic DNA, recognizing double-stranded DNA (dsDNA) derived from abnormally localized nuclear DNA or mitochondri...
Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy [0.03%]
通过纳米粒子介导的STING激动剂协同作用增强放疗诱导的抗肿瘤免疫响应
Qian Zeng,Min Liu,Ziqi Wang et al.
Qian Zeng et al.
Radiotherapy (RT) remains a cornerstone treatment for over 50% of cancer patients, primarily via ionizing radiation-induced DNA damage to exert therapeutic effects. Notably, emerging studies have revealed its additional capacity to activate...
Correction: Proteogenomic characterization of molecular and cellular targets for treatment‑resistant subtypes in locally advanced cervical cancers [0.03%]
订正：局部晚期宫颈癌治疗抵抗亚型的蛋白质基因组特征及其分子和细胞靶点分析
Do Young Hyeon,Dowoon Nam,Hye-Jin Shin et al.
Do Young Hyeon et al.
Published Erratum
Molecular cancer. 2025 Jun 11;24(1):174. DOI:10.1186/s12943-025-02373-z 2025
Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial [0.03%]
安罗替尼联合白蛋白紫杉醇作为晚期食管鳞癌化疗免除的一线治疗：一项探索性多中心单臂二期临床试验
Xiangrui Meng,Xiuli Yang,Yonggui Hong et al.
Xiangrui Meng et al.
Background: No combined antiangiogenic and PD-1/PD-L1 blockade therapy has been investigated as a chemo-free first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). This study evaluates the efficacy a...
Clinical Trial
Molecular cancer. 2025 Jun 11;24(1):175. DOI:10.1186/s12943-025-02376-w 2025
Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC [0.03%]
单细胞转录组揭示MASH向HCC转化过程中免疫微环境的重编程
Yu Huang,Ying Xie,Yuqing Zhang et al.
Yu Huang et al.
Background: The immunological landscape of metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC) is not well understood. Herein, we aim to delineate the immunological landscape in t...